Research Article

Poststroke Hip Fracture: Prevalence, Clinical Characteristics, Mineral-Bone Metabolism, Outcomes, and Gaps in Prevention

Table 5

Clinical and laboratory characteristics independently associated with poststroke hip fracture.

CharacteristicModel 1Model 2Model 3
OR95% CI valueOR95% CI valueOR95% CI value

Female sex3.731.11–12.590.0343.641.17–11.420.0263.581.03–12.450.045
TIA5.171.62–16.480.0055.171.59–16.790.006
Dementia4.161.56–11.050.0044.141.79–9.590.001
Hypertension3.341.37–8.140.0083.201.29–7.910.012
CAD2.701.03–7.070.0432.410.97–5.970.057
Use of walking aid2.201.03–5.090.0432.471.08–5.650.032
Vitamin B12 > 350 pmol/L2.351.05–5.490.0392.331.03– 5.250.042
0.2210.1260.225
Mean V1F1.191.251.03

OR: odds ratio; CI: confidence interval; TIA: transient ischaemic attack; CAD: coronary artery disease; VIF: variance inflation factor.
Model 1 (clinical parameters) adjusts for age, sex, dementia, hypertension, CAD, history of myocardial infarction, TIA: atrial fibrillation, renal impairment (eGFR < 60 mL/min/1.73 m2), use of walking aid, and living in a long-term residential care facility.
Model 2 (laboratory parameters) adjusts for age, sex, vitamin D insufficiency (25(OH)D < 50 nmol/L), elevated PTH (>6.8 pmol/L), and high bone resorption markers (DPD/Cr > 7.5 mmol/ mol, NTX/Cr > 65 mmol/ mol).
Model 3 (combined clinical and laboratory parameters) adjusts for al variables in Models 1 and 2.